Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Upwork Inc (UPWK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Upwork Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Upwork Inc trades at $8.89 (market cap $1.09B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 36.6× Upwork Inc's market cap. Which is the better fit depends on your goals.
| ALNY | UPWK | |
|---|---|---|
Market Cap | $39.89B | $1.09B |
Sector | Health | Industrials |
52-Week High | $491.22 | $22.11 |
52-Week Low | $278.09 | $7.84 |
Enterprise Value | $38.15B | $890.41M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
UPWK trades at $8.82, up 1.61% today, but faces a bearish technical signal with recent earnings misses in Q3 2025, Q4 2025, and Q1 2026. The company reported 2025 revenue of $787.78M with a net income margin of 13.81%, while valuation metrics like a P/E of 10.9 and P/S of 1.55 appear reasonable. However, multiple law firms are investigating potential securities fraud, contributing to negative sentiment after a 19% stock drop post-Q1 2026 results.
The outlook is mixed: analyst consensus is a Buy with a $10.67 price target, but risks include ongoing legal probes, earnings volatility, and competitive pressures in the gig economy. Upside depends on execution improvements and AI integration initiatives like the Upwork Claude Connector announced in June 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
